

\*\*\*\*Updated June 2011\*\*\*\*

## MarketVIEW: *Chlamydia trachomatis* vaccines (CAT: VAMV003)

<b>Proposal No/#PO</b>	:	<b>[Enter client specific #PO]</b>
<b>Product Name</b>	:	MarketVIEW: <i>Chlamydia trachomatis</i> vaccines – Global market forecast
<b>Project Initiation Date</b>	:	n/a
<b>Billable days</b>	:	n/a
<b>Initiator(s)</b>	:	[Enter client name, function and address]
<b>Therapeutic Area</b>	:	<i>Adolescent vaccines</i>
<b>Product (if applicable)</b>	:	<b>CAT No:</b> VAMV003, updated June 2011

## Background

After the global success of new HPV vaccines focused on sexually transmitted infections (STDs), vaccine manufacturers are considering other high-burden infections in the adolescent group, especially *Chlamydia trachomatis* (CT). CT is a major cause of serious reproductive complications in the female with outcomes such as pelvic inflammatory disease (PID) and ectopic pregnancies. Although diagnosed infections with *Chlamydia trachomatis* are curable with antibiotic therapy, the vast majority infections are “silent” and unrecognized. Even after treatment re-infection rates of CT remain high with little chance of eradication within the population.

This **MarketVIEW** product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of a prophylactic *Chlamydia* vaccine across the major Western and emerging markets (BRIC-M). The model contains value (\$ m) and volume (mio doses) predictions along with launch timeframe, pricing and penetration estimates.

**LO/BASE/HI** forecast scenarios are included relative to Gardasil adoption as a case study. The impact of country dependent National Immunization Programs and funded “catch-up” campaigns is also studied.

## Methodology

**VacZine Analytics** has closely monitored all significant source material pertaining to *Chlamydia trachomatis* epidemiology/vaccines and consulted with global experts regarding their predictions of vaccine deployment. Secondary source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by **VacZine Analytics** in the adolescent field has also been utilised.

### PRODUCT CONTENTS:

**Published June 2011 (CAT No: VAMV003)**

\*\*\*\*This product is composed of a model and summary presentation

#### Contents – Summary presentation (MS PowerPoint based)

Author's note  
Executive Summary  
Commercial model – key outputs  
Total available market: Chlamydia vaccine (all scenarios) (\$ 000s)  
Total available market: Chlamydia vaccine (girls 13 yrs), West (\$ 000s)  
Total available market: Chlamydia vaccine (females 14 – 18 yrs), West (\$ 000s)  
Total available market: Chlamydia vaccine (girls 13 yrs), Emerging (\$ 000s)  
Total available market: Chlamydia vaccine (females 14 – 18 yrs), Emerging (\$ 000s)  
Chlamydia vaccine: segment volume analysis (000s doses)  
Chlamydia vaccine: segment value analysis (\$ 000s)  
Chlamydia trachomatis: brief background  
Chlamydia trachomatis: clinical features  
Chlamydia trachomatis: treatment options  
Chlamydia trachomatis: natural history of infection  
Chlamydia trachomatis: global incidence  
Chlamydia trachomatis: global prevalence  
US epidemiology  
UK epidemiology  
EU epidemiology  
Reasons for increasing incidence  
Commercial model – key assumptions  
Chlamydia vaccine opportunity: target product profile  
Overall commercial model assumptions  
Population segments included in model: scenario definition  
Chlamydia vaccine market adoption  
Overall commercial model assumptions per country  
Competitive environment: major players  
Competitive environment: other players  
Chlamydia trachomatis vaccine – HPV, a relevant case study?  
HPV: analysis of country uptake  
Chlamydia trachomatis vaccine: key potential upsides  
Bibliography  
Disclaimer  
About **VacZine Analytics**

**PAGES: ~50 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form**

**Contents – Vaccine demand model (MS Excel-based)**

Title Sheet  
Scenario definition  
Value Scenario Analysis  
Value Summary (Western)  
Volume Summary (Western)  
Value Summary (Emerging)  
Volume Summary (Emerging)  
Charts – volume (Western)  
Charts – value (Western)  
Charts – value/volume (Western)  
Females (Western) →  
US (13 yrs/ 14 - 18 yrs)  
Canada  
UK  
France  
Germany  
Italy  
Spain  
Other EU  
Australia  
Japan  
Females (Emerging) →  
Brazil  
Russia  
India  
China  
Mexico  
Population database  
Competition – IP landscape  
Assumptions – major markets  
Back page  
About VacZine Analytics  
Disclaimer

**WORKSHEETS: ~65**

## PRODUCT COST:

**VacZine Analytics** will grant a [enter region] license to [enter client name], for the price of:

- o USD \$7995.00/ GBP £4995.00 (Region license)\*


\*A region is North America, Europe or ROW

For orders in the UK, VAT at 20 % will be added to final invoice total

## HOW TO ORDER:

To order please contact your region account manager or order direct at [orders@vaczine-analytics.com](mailto:orders@vaczine-analytics.com)

This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



**VacZine Analytics (R)** is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

**VacZine Analytics (R)** and the “**spiral logo**” are UK Registered Trademarks, 2009

## Bibliography

1. Nogales MC. [Diagnosis of Chlamydia trachomatis infection in a clinic for sexually transmitted disease: evaluation of cervical, urethral and rectal swab samples by polymerase chain reaction] *Enferm Infecc Microbiol Clin*. 2007 Jan;25(1):11-5.
2. Katz BP. Estimation of transmission probabilities for chlamydial infection. In: International symposium on human chlamydial infections. Chlamydia infections: proceeds of the seventh international symposium on human chlamydial infections. New York: Cambridge University Press, 1990:567-70
3. Niccolai LM Burden of recurrent Chlamydia trachomatis infections in young women: further uncovering the "hidden epidemic". *Arch Pediatr Adolesc Med*. 2007 Mar;161(3):246-51. *Ann Intern Med*. 2006 Oct 17;145(8):564-72.
4. Simms I. Has the incidence of pelvic inflammatory disease following chlamydial infection been overestimated? *Int J STD AIDS*, April 1, 2008; 19(4): 285 – 286
5. Silins I. Chlamydia trachomatis infection and persistence of human papillomavirus. *Int J Cancer*. 2005 Aug 10;116(1):110-5.
6. US Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines 2010. Available at: <http://www.cdc.gov/std/treatment/2010/default.htm>
7. Brunham RC. The unexpected impact of a Chlamydia trachomatis infection control program on susceptibility to reinfection. *J Infect Dis*. 2005 Nov 15;192(10):1836-44
8. WHO. Global prevalence and incidence of selected curable sexually transmitted infections: overview and estimates. Geneva: World Health Organization, 2001
9. Vaccines and Related Biological Products Advisory Committee May 18, 2006. GARDASIL Quadrivalent HPV (Types 6, 11, 16, 18) L1 VLP Vaccine, Merck Research Laboratories. Available at: <http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4222s-index.htm>. Accessed: June 2011
10. Centers for Disease Control and Prevention. 2009 Sexually Transmitted Diseases Surveillance STD Surveillance Report. Available at: <http://www.cdc.gov/std/stats09/chlamydia.htm>. Accessed: June 2011.
11. Centers for Disease Control and Prevention. 2009 Sexually Transmitted Diseases Surveillance. Available at: <http://www.cdc.gov/std/stats09/figures/5.htm>. Accessed: June 2011.
12. UK Health Protection Agency. STIs Annual Slide Set 2000 – 2009. Available at: <http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/STIs/STIsAnnualData/AnnualSTISlideset/>. Accessed June 2011
13. Annual HPV vaccine coverage in England in 2009/2010. [http://www.dh.gov.uk/prod\\_consum\\_dh/groups/dh\\_digitalassets/documents/digitalasset/dh\\_123826.pdf](http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_123826.pdf)
14. Quadrivalent Human Papilloma Virus Vaccine. *MMWR Recommendations and Reports*. March 23 2007 /56 (RR02);1 -24
15. Centers for Disease Control and Prevention. National, state, and local area vaccination coverage among adolescents aged 13-17 years --- United States, 2009. *MMWR Morb Mortal Wkly Rep*. 2010 Aug 20;59(32):1018-23. Available at: <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5932a3.htm>. Accessed: 18 June 2011.
16. Complete HPV Immunization Rates Low in the United States, March 12, 2010. Available at: <http://www.medscape.com/viewarticle/718413>
17. Dorleans F., et al. The current state of introduction of HPV vaccination into national immunization schedules in Europe: First results of the VENICE2 2010 survey. *Eurosurveillance*, Volume 15, Issue 47, 25<sup>th</sup> November 2010

## TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client's acceptance of the Service according the description proposed by the Company.
3. **Cancellation policy.** The Company's cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client's cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request.

### VacZine Analytics

Warren House  
Bells Hill  
Bishops Stortford  
Herts  
CM23 2NN  
United Kingdom  
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926  
E-mail: [info@vacZine-analytics.com](mailto:info@vacZine-analytics.com)

## About VacZine Analytics:

**VacZine Analytics** is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website [www.vacZine-analytics.com](http://www.vacZine-analytics.com)

**VacZine Analytics (R)** is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

**VacZine Analytics (R)** and “the spiral logo” are UK Registered Trademarks, 2009